Dianthus Posts $46.6M Q3 Loss, Touts 75% CIDP Response Rate and $1.2B Cash Into 2030
DNTH has more than doubled off its 52-week low of $32.42 on elevated volume (2.0× avg).
Summary
Dianthus reported a $46.6M net loss for Q3 2026, or $0.81 per share, versus $36.8M a year ago, with R&D spending up to $45.6M on claseprubart Phase 2/3 costs and early pipeline work. The clinical update is the real story: a 75% response rate in the interim responder analysis of the first 40 CAPTIVATE Part A patients in CIDP, above the 50% target set from prior aC1s precedent, with no related serious infections or drug-induced lupus. CAPTIVATE Part A enrollment is now projected under 200 patients to randomize 128 responders into Part B, with Part A top-line by YE'27 and Part B by YE'28. The Phase 2 MoMeNtum MMN trial beat its 36-patient enrollment target and will report top-line data on 46 patients in December 2026, ahead of a planned Phase 3 in 2027. Roughly $1.2B in cash funds operations into 2030, so there is no near-term financing need despite the $500M ATM shelf filed in September. December's MoMeNtum readout is the next binary event for the stock.
At the time of this announcement, DNTH was trading at $85.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $32.42 to $117.88. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.